The Medlior team is pleased to present their research project The Impact Of Treatment Adherence On Clinical And Economic Outcomes In Multiple Sclerosis: Real-World Evidence From Alberta, Canada (sponsored by Novartis Pharmaceuticals Canada Inc.), at the ISPOR 19th Annual European Congress, October 31, 2016 in Vienna, Austria.
The study utilized patient data from Alberta Health and Alberta Health Services to assess the impact of medication adherence to disease-modifying therapy (DMT) on healthcare resource utilization among multiple sclerosis (MS) patients in Alberta, Canada.
Study highlights include:
- 2864 MS patients identified using a validated MS case-definition
- The majority of patients were females aged 35 – 55 years old
- The most common comorbidities included depression, anxiety, and hypertension
- 66% of MS patients were adherent (MPR ≥ 0.80) during the one-year follow-up
- After adjusting for potentially confounding variables, adherent patients experienced reductions in physician claims (~20%), ambulatory care visits (~20%), and hospitalizations (~50%)
These findings have important implications for shared decision-making among patients and providers as well as health system administrators for the management of MS patients. Further research into treatment adherence among patients with chronic conditions, utilizing real world evidence sources, may provide further insights into clinical and economic outcomes.
For more information or for a copy of the poster, please contact the corresponding author Brittany Gerber
Written by: Brittany Gerber